US/UK/Canada

Share

Pick a time period -
Tags ( Active)

DanCann Pharma A/S: The Danish Government Proposes Permanent Scheme for Prescription-Based Medicinal Cannabis for Danish Patients

COPENHAGEN, Denmark, 19 November 2024 – DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”), a Danish company powered by cannabinoids, hereby announces that the Danish government has expressed its intention to make the Pilot Programme for prescription-based medicinal cannabis permanent. This proposal will be presented today by the Minister of the Interior and Health, Sophie Løhde, during negotiations with the political parties supporting the initiative. The decision is based on a recent evaluation that highlights a significant increase in the number of prescriptions filled,

DanCann Pharma A/S: Capital reduction in DanCann Pharma A/S is completed

The capital reduction in DanCann Pharma A/S as resolved on an extraordinary general meeting held on 7 October 2024 has been completed today, 5 November 2024, following expiry of a 4-week notice period ("proklama").As set out in press release published on 7 October 2024, at an extraordinary general meeting in DanCann Pharma A/S held on 7 October 2024 it was resolved to reduce the share capital of the Company by nominally DKK 13,869,911.106 from nominally DKK 15,411,012.34 to nominally DKK 1,541,101.234 by transfer of the amount to a special reserve fund (in Danish: henlæggelse til særlig

Minutes of extraordinary general meeting

held in DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”)(Please note: The capital reduction (item 1) and the resulting amendments of the articles of association cannot be completed before expiration of the 4-week notice period (“proklama”) which commences today. Attached are updated articles of association without the capital reduction (effective today) and updated articles of association including the capital reduction). On 7 October 2024 at 09:00 am (CET), an extraordinary general meeting was held in the Company at the Company’s address, Rugvænget 5, 6823 Ansager, Denmark.

DanCann Pharma A/S: Calls for an Extraordinary General Meeting regarding New Authorizations and Reduction of Share Capital in Preparation for Reverse Stock Split

COPENHAGEN, Denmark, 24 September 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, announces further details regarding the notice of an extraordinary general meeting ("EGM") and the matters to be discussed.DanCann Pharma has called for an EGM to be held on Monday, 7 October 2024 at 09:00 am (CET), based on the recommendation of the Board of Directors. At the EGM, it will be proposed to reduce the Company’s nominal share capital by transferring the amount to a special reserve fund. The capital reduction is completed by way

NOTICE OF EXTRAORDINARY GENERAL MEETING IN DANCANN PHARMA A/S

The Board of Directors hereby convenes an extraordinary general meeting of DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”), to be held on Monday, 7 October 2024 at 09:00 am (CET) at DanCann Pharma A/S’ address, Rugvænget 5, 6823 Ansager, Denmark The agenda for the extraordinary general meeting is as follows: Proposed resolution to reduce the Company's share capital by transfer of 1. the amount to a special reserve fund (in Danish: henlæggelse til særlig  reserve) by way of reduction of the nominal value per share of the Company, including consequential

DanCann Pharma A/S: Number of Reported Suspected Adverse Reactions Drops by Two-Thirds in 2023 Despite 72% Growth in the Medicinal Cannabis Pilot Programme

COPENHAGEN, Denmark, 18 September 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby provides a status on the ongoing monitoring of the Pilot Programme for medicinal cannabis.As part of the ongoing monitoring of the Pilot Programme for medicinal cannabis, the Danish Medicines Agency has released a report on the reporting of suspected adverse reactions, cannabis end-products, and the consumption status for 2023. In 2023, the Danish Medicines Agency received a total of three reports of suspected adverse reactions

DanCann Pharma A/S: Quarterly CEO Reflection

COPENHAGEN, Denmark, 14 August 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces the CEO’s reflections following the publication of the Company’s Q2-2024 report.CEO, Jeppe Krog Rasmussen, comments:   Financials: Record revenue and positive EBITDA DanCann Pharma closed Q2-2024 with a record revenue of DKK 3.86 million. For H1-2024, this resulted in a further record revenue of approximately DKK 4.55 million. Comparing this to the revenue of DKK 2.90 million for H1-2023, we have amassed an increase of

DanCann Pharma A/S Publishes Q2-2024 Report: Record Revenue and First-Ever Positive EBITDA

COPENHAGEN, Denmark, 14 August 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the second quarter of 2024. The Q2-2024 report is available as an attached document to this press release and at www.dancann.com.SUMMARY: GROUP KEY FIGURES Q2-2024 +-----------+----------+----------+----------+----------+-------------------+|DKK 1,000 |01/04/24 |01/04/23 |01/01/24 |01/01/23 |01/01/23 - 31/12/23|| |- 30/06/24|- 30/06/23|- 30/06/24|- 30/06/23|

DanCann Pharma A/S announces last day for trading in temporary shares

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, RUSSIA, BELARUS, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. COPENHAGEN, Denmark, 3 July 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces that the rights issue of shares that was

DanCann Pharma A/S announces outcome of the Rights Issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, RUSSIA, BELARUS, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. COPENHAGEN, Denmark, 27 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces the outcome of the rights issue of shares

DanCann Pharma A/S: Last day of subscription of shares in the ongoing Rights Issue is 20 June 2024 on Nordnet Bank and Avanza Bank

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SINGAPORE, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.   COPENHAGEN, Denmark, 19 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announces that Thursday, 20 June 2024 at 13:59 CET, is the last day

DanCann Pharma A/S: Solid growth in the Rx portfolio

COPENHAGEN, Denmark, 18 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby provides an update on its current portfolio and expectations for the year ahead.Key highlights from the portfolio[1] and pipeline[2]: · Growth in 2023: Achieved a sales growth of +40% year-over-year (YoY) in pharmacy sales. · Sales volume: This growth equated to +14,000 packages of medicine. · 2024 projections: The Company aims to further increase the current Rx portfolio sales volume to 20,000 packages in 2024, representing a

DanCann Pharma A/S: Germany trends – prescriptions for medicinal cannabis positively influenced by new legalization

COPENHAGEN, Denmark, 14 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, announces key insights into the recent legalization of cannabis in Germany ("CanG"), which came into effect on April 1, 2024.Key highlights from CanG: · Declassification: Cannabis is no longer classified as a narcotic but as a regular (off-label-use) medicine. · Elimination of risk assessment: No longer required to assess risks such as possible addiction when prescribing medicinal cannabis. · Simplified prescription process: Abolition

DanCann Pharma A/S: Submits applications for FLS03 and FLS04 to expand portfolio

COPENHAGEN, Denmark, 12 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, has formally submitted applications for two additional medicines to enrich the existing portfolio with the Danish Medicines Agency under the Danish Pilot Programme for medicinal cannabis.Submission of two new applications: · FLS04, CBD-granulate · FLS05, THC-flos The applications encompass two new medicines, poised to complement the current trio of approved products (Bedrocan®, Bedica®, and Bediol®). These include a THC-dominant

DanCann Pharma A/S: The subscription period of DanCann Pharma’s Rights Issue begins today

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SINGAPORE, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURESCOPENHAGEN, Denmark, 11 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announces that the subscription period of DanCann Pharma’s rights issue of

DanCann Pharma A/S: Publishes Q1-2024 Report

COPENHAGEN, Denmark, 01 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the first quarter of 2024 (“Q1-2024”). The Q1-2024 report is available as an attached document to this press release and at www.dancann.com.Summary: Group Key Figures Q1-2024 DKK 1,000 01/01/24 01/01/23 01/01/23 – 31/12/23 01/01/22 – 31/12/22 –31/03/24 –31/03/23 Net sales: 702 620 6,073 5,708 Operating -2,645 -4,

DanCann Pharma A/S: Minutes OF ANNUAL GENERAL MEETING

held in DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”)Thursday, 30 May 2024 at 09:00 am (CET) On 30 May 2024 at 09:00 am (CET), the annual general meeting of 2024 was held in the Company at the Company’s address, Rugvænget 5, 6823 Ansager, Denmark. The agenda for the annual general meeting was as follows: 6. `. 1. 1. 1. 1. 1. The chairman’s report on the activities of the Company in the past financial year 2. Adoption of the annual report for 2023 3. Covering of loss pursuant to the adopted

DanCann Pharma A/S: The Board of Directors has resolved on a partially (48.88 percent) secured Rights Issue of approximately DKK 18.33 million and publishes memorandum

COPENHAGEN, Denmark, 24 May 2024 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announces that the Board of Directors of DanCann Pharma today has formally resolved on the previously announced partially (48.88 percent) guaranteed rights issue of shares with a total offer volume of approx. DKK 18.33 million (the “Rights Issue”). The resolution was adopted based on the authorisation from the extraordinary general meeting of the Company held on the 17 April 2024.The Rights Issue in short: · The Offer is comprised by a

DanCann Pharma A/S: Capital reduction completed

The capital reduction in DanCann Pharma A/S as resolved on an extraordinary general meeting held on 17 April 2024 has been completed today, 16 May 2024, following expiry of a 4-week notice period ("proklama").As set out in press release published on 17 April 2024, an extraordinary general meeting held on 17 April 2024 resolved to reduce the share capital of the Company by nominally DKK 4,582,269.6975 from nominally DKK 6,248,549.5875 to nominally DKK 1,666,279.89 by transfer of the amount to a special reserve fund (in Danish: henlæggelse til særlig reserve), cf. article 188(1)(3) of the

NOTICE OF ANNUAL GENERAL MEETING 2024 IN DANCANN PHARMA A/S

The Board of Directors hereby convenes the annual general meeting of DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”), to be held on Thursday, 30 May 2024 at 09:00 am (CET) at DanCann Pharma A/S’ address, Rugvænget 5, 6823 Ansager, Denmark The agenda for the annual general meeting is as follows: 1. 1. 1. 1. 1. 1. 2. The chairman’s report on the activities of the Company in the past financial year 3. Adoption of the annual report for 2023 4. Covering of loss pursuant to the adopted annual report for 2023 5. Election of

DanCann Pharma A/S Publishes Its Annual Report for 2023: A Year of Strategic Review and Future Focus on Capital Efficiency and Profitability

COPENHAGEN, Denmark, 15 May 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that The Board of Directors and the Chief Executive Officer of DanCann Pharma publishes the annual report of the year 2023. The annual report is available in this press release and on the website of DanCann Pharma.Financial highlights for 2023:  · Revenue for 2023 amounted to DKK 6.07 million (2022: DKK 5.71 million).   · Net loss in 2023 amounted to DKK -62.26 million (2022: DKK -16.06 million).* · As of December 31,

DanCann Pharma A/S: Updated time plan and material terms of the rights issue

COPENHAGEN, Denmark, 15 May 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, published (on 30 March 2024) that the Company intends to carry out a rights issue, and that the offer memorandum was planned to be published on 16 May 2024. However, the date of publication of the offer memorandum has been postponed to 24 May 2024, and the time plan for the rights issue has been postponed correspondingly. Updated time plan and material terms of the rights issue are further described above.As set out in press release published on

DanCann Pharma A/S: MINUTES OF EXTRAORDINARY GENERAL MEETING

held in DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”)On 17 April 2024 at 09:00 am (CET), an extraordinary general meeting was held in the Company at the Company’s address, Rugvænget 5, 6823 Ansager, Denmark. The agenda for the extraordinary general meeting was as follows: Proposed resolution to reduce the Company's share capital by transfer of 1. the amount to a special reserve fund (in Danish: henlæggelse til særlig reserve) by way of reduction of the nominal value per share of the Company, including consequential amendments to the articles of association

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media

Rss